Susser Petroleum Partners Enters Oversold Territory (SUSP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.

In trading on Tuesday, shares of Susser Petroleum Partners LP ( SUSP) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $30.06 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 67.9. A bullish investor could look at SUSP's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of SUSP shares:

START SLIDESHOW:
Find out what 9 other oversold stocks you need to know about »

Susser Petroleum Partners LP 1 Year Performance Chart

Looking at the chart above, SUSP's low point in its 52 week range is $22.80 per share, with $33.41 as the 52 week high point — that compares with a last trade of $30.35.

According to the ETF Finder at ETF Channel, SUSP makes up 1.46% of the Dynamic Energy Sector Portfolio ETF ( PXI) which is trading up by about 0.9% on the day Tuesday.

null

More from Stocks

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Trump's 'Space Force' Could Launch a $1 Trillion Industry, Morgan Stanley Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says

Abiomed Stock Should Rise Some 12% From Here, Piper Jaffray Analyst Says